Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Other Operating Expenses (2017 - 2023)

Historic Other Operating Expenses for BeOne Medicines (BEIGF) over the last 7 years, with Q2 2023 value amounting to $188000.0.

  • BeOne Medicines' Other Operating Expenses fell 9973.66% to $188000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $188000.0, marking a year-over-year increase of 10028.82%. This contributed to the annual value of $71.5 million for FY2020, which is 139.69% down from last year.
  • As of Q2 2023, BeOne Medicines' Other Operating Expenses stood at $188000.0, which was down 9973.66% from $187000.0 recorded in Q1 2023.
  • Over the past 5 years, BeOne Medicines' Other Operating Expenses peaked at $76.7 million during Q3 2022, and registered a low of -$213.5 million during Q4 2022.
  • For the 5-year period, BeOne Medicines' Other Operating Expenses averaged around $8.0 million, with its median value being $19.4 million (2019).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 22908.4% in 2019, then tumbled by 64981.66% in 2021.
  • Over the past 5 years, BeOne Medicines' Other Operating Expenses (Quarter) stood at $18.3 million in 2019, then increased by 16.11% to $21.3 million in 2020, then plummeted by 649.82% to -$116.9 million in 2021, then crashed by 82.61% to -$213.5 million in 2022, then surged by 100.09% to $188000.0 in 2023.
  • Its Other Operating Expenses stands at $188000.0 for Q2 2023, versus $187000.0 for Q1 2023 and -$213.5 million for Q4 2022.